Dova Pharmaceuticals Inc., based in Durham, North Carolina, dismissed accounting firm KPMG as its auditor on March 21 and replaced it with Ernst & Young, according to a filing with the Securities and Exchange Commission.

KPMG had been Dova’s auditor since the company’s inception in March 2016. The filing reported Dova’s audit committee approved the appointment.

KPMG’s financial statements for Dova included an explanatory paragraph saying there was “substantial doubt about the company’s ability to continue as a going concern.” The statement is typical for startup drug companies with no products on the market.

In a March 27 letter to the SEC, KPMG said it agreed with Dova’s filing, but it can’t confirm if the change was approved by the audit committee.

Dova is a clinical-stage pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need. The company has an initial focus on addressing thrombocytopenia.

A new drug application for avatrombopag. which treats thrombocytopenia in patients with chronic liver disease, was accepted and granted priority review by the U.S. Food and Drug Administration in the fourth quarter.

The company announced plans to submit a new drug application in the second half of 2018 for the treatment of patients with immune thrombocytopenic purpura.

Dova reported a net loss of $9.3 million for the fourth quarter of 2017.

Dova shares were at $26.57 during Wednesday afternoon trading, down 2 percent from its opening price.